January 30, 2012 — Positron Corp., a molecular imaging healthcare company specializing in the field of nuclear cardiology, announced Jan. 23 that its wholly owned subsidiary, Manhattan Isotope Technology (MIT), received approval for its radioactive materials license amendment. The Texas Department of State Health Services -- Radiation Control Program granted the amendment approval.

January 30, 2012 — Medtronic, Inc. announced the completion of patient enrollment in the extreme risk study in its CoreValve United States Pivotal Trial. The company received approval from the U.S. Food and Drug Administration (FDA) for an extended investigation (under the FDA’s Continued Access Policy) to continue enrolling extreme risk patients under a Continued Access Study protocol.

January 30, 2012 — Expanded cholesterol assessment of moderate risk patients can play an important role in identifying and monitoring the progression of atherosclerosis. That’s according to a clinical study that used the Vertical Auto Profile (VAP) cholesterol test to analyze lipids potentially associated with carotid intima-media thickness (CIMT).

The 2012 American College of Cardiology (ACC) meeting in Chicago, March 24-26, includes five sessions of late-breaking trials. The ACC announced the following trials will be included:

January 27, 2012 — A miniature, battery-free, wireless, cardiac implant being developed by a University of Michigan researcher and the Ann Arbor, Mich., company Integrated Sensing Systems, Inc. (ISSYS), has received funding that could get it to patients more quickly.

January 27, 2012 — Crux Biomedical announced it received CE mark approval for its inferior vena cava filter (IVCF) with bi-directional retrieval (BDR).  Vena cava filters are designed to trap blood clots that can lead to a potentially fatal pulmonary embolism (PE).  Each year in the United States, approximately 600,000 patients develop a PE and an estimated 200,000 deaths occur.

January 27, 2012 — Arizona Heart has chosen Ziehm digital flat-panel C-arms for its three advanced technology suites. The Ziehm Vision RFD hybrid edition delivers distortion-free, high-resolution images for interventional procedures, and represents a cost-efficient alternative solution to fixed installed systems.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now